6 completed, 3 terminated, 3 unknown, 2 withdrawn. 15 Phase 2, 4 Phase 1, 3 Phase 3.
Follow Hypertrophic Scar: new trials by email Literature Review of Hypertrophic Scar trials Research Report on Hypertrophic Scar
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intra-lesional ACE Inhibitor for Treatment of Hypertrophic Scars Intralesional enalaprilat injection - Hypertrophic Scar | Phase 2 / Phase 3 | Withdrawn | Nova Scotia Health Authority | 2024-08-01 | 2025-02-17 | |
| A Study to Evaluate the Safety, Tolerability and Efficacy of AK3280 Cream on Hypertrophic Scar AK3280 Cream, Placebo cream - Hypertrophic Scar | Phase 1 / Phase 2 | Completed | Shanghai Ark Biopharmaceutical Co., Ltd. | 30 | 2022-07-08 | 2026-06-22 |
| Randomized Controlled Trial Examining the Efficacy of Botulinum Toxin in Biopsy Scar Minimization Botulinum Toxin, Normal saline - Scar, Hypertrophic Scar | Phase 2 / Phase 3 | Active not recruiting | Henry Ford Health System | 12 | 2022-06-01 | 2026-01-15 |
| Safety, Tolerability, Pharmacokinetics, Immunogenicity and Efficacy of STP705 in Adult Patients With Hypertrophic Scars STP705 - Hypertrophic Scar | Phase 1 / Phase 2 | Withdrawn | Sirnaomics | 2021-12-07 | 2026-07-29 | |
| Study to Evaluate Efficacy of OLX10010 in Reducing Recurrence of Hypertrophic Scarring After Scar Revision Surgery OLX10010 - Hypertrophic Scar | Phase 2 | Completed | Olix Pharmaceuticals, Inc. | 22 | 2021-08-19 | 2024-02-21 |
| Use of Autologous Platelet-Rich Plasma to Treat Hypertrophic Burn Scars PRP Injection, Saline Injection - Hypertrophic Scar | Phase 2 | Terminated | Vanderbilt University Medical Center | 3 | 2020-09-18 | 2023-01-09 |
| Clinical Safety and Scar Prevention Study of a Topical Antifibrotic Compound FS2. Fibrosis-Inhibiting-Compound-FS2, Vehicle moisture balancing base - Scar, Cicatrix | Phase 2 | Unknown | University of British Columbia | 50 | 2019-12-05 | 2019-12-17 |
| the Hypertrophic Scar Prevention of BMT101. BMT101 - Hypertrophic Scar | Phase 2 | Terminated | Hugel | 20 | 2019-08-21 | 2023-05-24 |
| The Efficacy and Molecular Mechanism of Botulinum Toxin in the Reduction of Breast Reduction Mammoplasty Scar Formation Botulinum Toxins, Normal saline - Scar, Hypertrophic Scar | Phase 2 / Phase 3 | Completed | Henry Ford Health System | 22 | 2019-06-10 | 2025-06-15 |
| Light Emitting Diode-Red Light (LED-RL) Phototherapy for Skin Scarring Prevention LED-RL phototherapy, Mock irradiation - Fibrosis, Skin Scarring | Phase 2 | Completed | State University of New York - Downstate Medical Center | 30 | 2019-03-18 | 2022-06-01 |
| Treatment of Hypertrophic Scars With Intradermal Botox Botox - Hypertrophic Scar | Phase 2 | Unknown | Roy G. Geronemus, M.D. | 20 | 2018-10-01 | 2018-09-26 |
| Hypertrophic Scar Prevention by Novel Topical Gel Application Pentamidine Isethionate, Placebo - Hypertrophic Scar | Phase 1 / Phase 2 | Terminated | Mayo Clinic | 6 | 2018-03-05 | 2023-11-22 |
| A Randomized Study to Evaluate the Safety and Efficacy of Various Doses of STP705 in Subjects With Hypertrophic Scar STP705, Placebo - Hypertrophic Scar | Phase 1 / Phase 2 | Completed | Sirnaomics | 25 | 2017-01-01 | 2021-11-24 |
| A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Revised Hypertrophic Scars RXI-109 - Hypertrophic Scar | Phase 2 | Unknown | RXi Pharmaceuticals, Corp. | 40 | 2014-07-01 | 2018-02-23 |
| A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery in Healthy Adults RXI-109, Placebo - Hypertrophic Scar | Phase 2 | Completed | RXi Pharmaceuticals, Corp. | 25 | 2013-11-01 | 2016-06-21 |
Cicatrix, Hypertrophic (15) · Cicatrix (8) · Keloid (3) · Breast Diseases (1) · Fibrosis (1) · Gigantomastia (1) · Hypertrophy (1)
Pathologic Processes (15) · Pathological Conditions, Signs and Symptoms (15) · Fibrosis (14) · Cicatrix (7) · Skin and Connective Tissue Diseases (4) · Collagen Diseases (3) · Connective Tissue Diseases (3) · Pathological Conditions, Anatomical (1) · Skin Diseases (1)
Botulinum Toxins (2) · Saline Solution (2) · abobotulinumtoxinA (2) · Botulinum Toxins, Type A (1) · Enalaprilat (1) · Pentamidine (1) · Sodium Chloride (1)
Henry Ford Health System (2) · RXi Pharmaceuticals, Corp. (2) · Sirnaomics (2) · Hugel (1) · Mayo Clinic (1) · Nova Scotia Health Authority (1) · Olix Pharmaceuticals, Inc. (1) · Roy G. Geronemus, M.D. (1) · Shanghai Ark Biopharmaceutical Co., Ltd. (1) · State University of New York - Downstate Medical Center (1) · University of British Columbia (1) · Vanderbilt University Medical Center (1)
United States (10) · China (2) · Honduras (2) · Canada (1) · South Korea (1)
David Ozog, MD (2) · Pamela Pavco, PhD (2) · Alexander Meves, MD (1) · Alexander Neumeister, MD (1) · Anthony Papp, MD, PhD (1) · Galen Perdikis, MD (1) · Jihong Liu (1) · Michael Bezuhly, MD, MSc (1) · Yan Wu (1)
PMID 10077078, PMID 11242330, PMID 11348456, PMID 12845617, PMID 15253184, PMID 16079683, PMID 18534768, PMID 18555763, PMID 18843115, PMID 19215252, PMID 19341651, PMID 19621835, PMID 19802513, PMID 20009818, PMID 20440184, PMID 21332916, PMID 22090252, PMID 22177632, PMID 22907286, PMID 23027220, PMID 23102873, PMID 24501476, PMID 24898579, PMID 27639820, PMID 28539239, PMID 28654594, PMID 29401161, PMID 30087573, PMID 30548742, PMID 31155638, PMID 31164358, PMID 31307501, PMID 31385893, PMID 31513335, PMID 32813130, PMID 7917152